Article Text

PDF
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies
  1. Mariano E Vega-Ostertag2,
  2. Elena Raschi3,
  3. Xiaowei Liu2,
  4. Zurina Romay-Penabad1,
  5. Valeria De Micheli4,
  6. Monica Galli5,
  7. Marco Moia6,
  8. Angela Tincani7,
  9. Maria Orietta Borghi8,
  10. Tracy Nguyen-Oghalai9,
  11. Pier Luigi Meroni8
  1. 1
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
  2. 2
    Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA
  3. 3
    Allergy, Clinical Immunology and Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy
  4. 4
    Ambulatorio Patologie Trombotiche e Emorragiche, Ospedale San Leopoldo Mandic, Merate, Italy
  5. 5
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
  6. 6
    Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
  7. 7
    Clinical Immunology and Rheumatology Service, Spedali Civili, Brescia, Italy
  8. 8
    Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy
  9. 9
    Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
  1. Dr Silvia S Pierangeli, Division of Rheumatology/Department of Internal Medicine, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-1165, USA; sspieran{at}utmb.edu

Abstract

Objective: A study was undertaken to investigate the in vivo pathogenic role of Toll-like receptor 4 (TLR-4) in the antiphospholipid syndrome (APS) by studying the thrombogenic antiphospholipid (aPL) activity in lipopolysaccharide (LPS) non-responsive (LPS–/–) mice and the association between tlr4 gene polymorphisms and APS in patients.

Methods: IgGs from two patients with APS, one with aPL negative systemic lupus erythematosus (SLE) and one with normal human serum (NHS), were evaluated for thrombosis, tissue factor (TF) activity and endothelial cell activation in LPS–/– mice displaying a tlr4 spontaneous mutation vs LPS responsive (LPS+/+) mice. Human tlr4 Asp299Gly and Thr399Ile polymorphisms were evaluated by allele-specific PCR in 110 patients with APS with arterial/venous thrombosis and in 220 controls of the same ethnic origin.

Results: IgG-APS produced significantly larger thrombi and more leucocytes (WBC) adhering to endothelial cells in the cremaster muscle microcirculation of LPS+/+ mice than IgG-NHS or aPL negative SLE-IgG. These effects were abrogated after absorption of the anti-β2glycoprotein I activity by an affinity column. The two IgG-APS induced significantly smaller thrombi and fewer WBC adhering to endothelial cells in LPS−/− mice than in LPS+/+ mice. IgG-APS induced higher TF activity in carotid artery homogenates of LPS+/+ mice than in LPS−/− mice. The prevalence of Asp299Gly and Thr399Ile tlr4 polymorphisms was significantly lower than in controls.

Conclusions: These findings in LPS−/− mice and the reduction in the “protective” polymorphism in patients with APS with thrombosis suggest that TLR-4 is involved in the interaction of aPL with endothelial cells in vivo.

Statistics from Altmetric.com

Footnotes

  • This study was partially funded by a Research Center in Minority Institution grant (NIH grant #G12-RR03034), a Minority Biomedical Research support grant from the NIH (#S02GMM08248) and Ricerca Corrente IRCCS Istituto Auxologico Italiano.

  • Competing interests: None.

  • Abbreviations:
    aCL
    anti-cardiolipin
    aPL
    antiphospholipid
    APS
    antiphospholipid syndrome
    β2GPI
    β2glycoprotein I
    EC
    endothelial cells
    LPS
    lipopolysaccharide
    NF-κB
    nuclear factor-κB
    NHS
    normal human serum
    SLE
    systemic lupus erythematosus
    SNP
    single nucleotide polymorphism
    TF
    tissue factor
    TLR
    Toll-like receptor

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.